Infectious Diseases

Our commitment to the fight against COVID-19

As a company with a long legacy of research in vaccines and infectious diseases, we’ve been committed to advancing an effective response to COVID-19 since it was first discovered.


Share this article


Covid-19 Header

«We’ve been focused on contributing our scientific expertise and experience to help address COVID-19.»


Our oral antiviral COVID-19 medicine

In collaboration with Ridgeback Biotherapeutics, we have advanced our research and development efforts for our COVID-19 medicine, making an important contribution to the care of COVID-19 patients.

We are working with health authorities to make our therapeutic option available worldwide.


Access to health care

We have a long track record of making our medicines and vaccines accessible and affordable. Our comprehensive supply and access strategy has enabled timely and broad access to our COVID-19 medicine for patients around the world, including in low- and middle-income countries. 

We have also provided UNICEF with up to 3 million treatment units for low- and middle-income countries.

Through our licensing agreements with generics manufacturers and the Medicines Patent Pool, more than 5 million courses of generic therapy have been delivered to 22 low- and middle-income countries through December 2022.


Our commitment as an employer

Throughout the COVID-19 pandemic, we’ve prioritized the health, safety and well-being of our employees and their families and supported our health care providers and our communities, including through volunteer work and donation efforts.

CH-NON-01216, 06/2023